Roberto Filippi
A5042064313- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gallbladder and Bile Duct Disorders
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Multiple and Secondary Primary Cancers
- Cancer Treatment and Pharmacology
- Metastasis and carcinoma case studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Diagnosis and Treatment
- Viral-associated cancers and disorders
- Bone health and treatments
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Liver Diseases and Immunity
- Helicobacter pylori-related gastroenterology studies
- Colorectal and Anal Carcinomas
- Peptidase Inhibition and Analysis
- Healthcare professionals’ stress and burnout
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
University of Turin
2016-2025
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2020-2025
Ospedale San Luigi Gonzaga
2023
Candiolo Cancer Institute
2015-2022
Istituti di Ricovero e Cura a Carattere Scientifico
2010-2021
Presidio Ospedaliero
2021
European Institute of Oncology
2010
University of Maryland, Baltimore
2008-2009
BACKGROUND Biliary tract cancer (BTC) is a rare and lethal disease with few therapeutic options. Preclinical data suggest that the epidermal growth factor receptor (EGFR) pathway could be involved in its progression. METHODS This open‐label, randomized phase 2 trial recruited chemotherapy‐naive patients advanced BTC displaying wild‐type (WT) KRAS status. Patients were to gemcitabine (1000 mg/m ) oxaliplatin (100 (arm A) or without B) panitumumab (6 mg/kg) for up 12 cycles. The primary...
Abstract Background Immunotherapy with immune checkpoint inhibitors (ICIs) is highly effective in microsatellite instability–high (MSI-H) metastatic colorectal cancer (mCRC); however, specific predictive biomarkers are lacking. Patients and Methods Data samples from 85 patients MSI-H mCRC treated ICIs were gathered. Tumor infiltrating lymphocytes (TILs) tumor mutational burden (TMB) analyzed an exploratory cohort of “super” responders “clearly” refractory patients; TILs then evaluated the...
The role of second-line chemotherapy (CT) is not established in advanced biliary tract cancer (aBTC). We investigated the outcome aBTC patients treated with CT and devised a prognostic model. Baseline clinical laboratory data 300 consecutive were collected association overall survival (OS) was by multivariable Cox models. following parameters resulted independently associated longer OS: Eastern Cooperative Oncology Group performance status 0 (P<0.001; hazard ratio (HR), 0.348; 95% confidence...
Abstract Background An accurate risk‐stratification is key to optimize the benefit‐to‐risk ratio of palliative treatment in advanced biliary cancer. We aimed at assessing impact prognostic nutritional index (PNI) on survival and response cancer (ABC) receiving first‐line chemotherapy. Methods Medical records ABC treated with standard chemotherapy Modena Cancer Centre were retrospectively reviewed for variables deemed potential interest, including PNI. Univariate multivariate analyses...
Second-line therapy has consistently demonstrated survival benefit if compared with best supportive care; however, there is limited evidence whether further lines of treatment may improve the prognosis advanced gastric cancer (AGC) patients.Starting from a real-world cohort 868 AGC patients, we retrospectively analyzed baseline parameters, tumor characteristics, and data those treated at least three lines. Categorical features were described through cross-tables chi-square test. We explored...
Our objective was to evaluate the prognostic value of somatostatin receptor tumor burden on 68Ga-DOTATOC PET/CT in patients with well-differentiated (WD) neuroendocrine tumors (NETs). Methods: We retrospectively analyzed scans 84 histologically confirmed WD NETs (51 grade 1, 30 2, and 3 3). For each scan, all 68Ga-DOTATOC-avid lesions were independently segmented by 2 operators using a customized threshold based healthy liver SUVmax (LIFEx, version 5.1). Somatostatin receptor-expressing...
Abstract The onset of multiple and metachronous tumors in young patients induces to suspect the presence genetic variants genes associated with tumorigenesis. We describe here unusual case a 16-year-old patient who developed synchronous bifocal colorectal adenocarcinoma distant metastases. provide high throughput molecular characterization whole-exome sequencing (WES) DNA targeted different tumoral lesions normal tissue samples that led unveil germline POLE mutation (p.Ser297Cys) coexisting...
495 Background: Immune-combinations have become the cornerstone of mRCC treatment landscape, but head-to-head comparisons between different first-line strategies are lacking and few real-world data available in this setting. In context, little evidence is available, especially for IMDC poor-risk patients, who worst prognosis lowest response to standard treatments. Methods: The Meet-URO 33 study an Italian retrospective/prospective registry setting patients from January 2021 (Trial...
5029 Background: Testis cancer (TC) is the most common solid neoplasm affecting men aged 15 to 40, with of diagnosis occurring at stage I. Despite excellent prognosis, optimal post-surgical management remains controversial, comprising adjuvant therapy (AT) or active surveillance (AS). Methods: Our study aimed compare relapse-free survival (RFS) in patients (pts) I TC undergoing AT [chemotherapy (CT) radiotherapy (RT)], versus AS, between 2000 and 2023. Evolution choices for seminomas was...
e16572 Background: Avelumab maintenance after first-line platinum-based chemotherapy represents a cornerstone for the treatment of metastatic urothelial carcinoma (mUC). However, identifying prognostic biomarkers is paramount optimizing patients’ benefits while minimizing toxicity. Systemic inflammatory indexes have been studied as immune checkpoint inhibitors in many tumor types, but their role mUC still debatable. We hypothesized that systemic could be correlated with survival patients...
Fluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred option in advanced biliary tract cancer (aBTC) (ABC-06 phase III trial). However, the overall survival (OS) benefit was limited and comparison with FP monotherapy not available. Our aim to assess OS of patients treated compared doublet irinotecan or L2. We performed retrospective analysis two large multicenter prospective cohorts: French cohort (28 centers) an Italian (9 centers)....
<b><i>Background and Aims:</i></b> In the last few years, there has been increasing interest in non-cancer medications their potential anti-cancer activity. Data are not available cholangiocarcinoma (CCA) patients. The aim of this study is to fill gap by investigating impact terms clinical outcome common medications. <b><i>Methods:</i></b> All consecutive patients with CCAs were retrospectively identified from 7 Italian medical institutions. We...
Abstract Background The burnout phenomenon has been extensively investigated among health care professionals, particularly focusing on physicians and nurses. However, literature concerning in clinical research is poor often neglects the other professional categories involved. Methods In March 2019, all members of Italian Group Clinical Research Coordinator were invited to participate a web survey, consisting three sections: general information workload; Maslach Burnout Inventory (MBI) test;...
Colorectal cancer (CRC) patients frequently develop liver metastases. Different treatment strategies are available according to the timing of appearance, burden metastatic disease, and performance status patient. Systemic (ST) represents cornerstone disease management. However, in select cases, combined ST surgical resection can lead remarkable survival outcomes. In present multicentric cohort study, we explored efficacy a conversion strategy selected population left-sided RAS/BRAF wild-type...
Fluoropyrimidines (FP) are the backbone chemotherapy in colorectal cancer (CRC) treatment; however, their use is associated with cardiotoxicity, which underreported. In present study, it was aimed to prospectively determine incidence rates and related risk factors of FP‑induced cardiotoxicity (FIC) CRC patients at identifying predictive biomarkers. A total 129 consecutive previously untreated underwent active cardiological monitoring, including 5‑items simplified questionnaire on symptoms,...